TLDR
- NLS and Kadimastem unite as NewCelX, debuting on Nasdaq Oct 31.
- Kadimastem exits TASE; NewCelX emerges as a global biotech player.
- NLS rebrands to NewCelX, fusing Swiss and Israeli biotech strengths.
- Nasdaq approves NLS-Kadimastem merger; trading shifts Oct 31.
- NewCelX to blend neuropharma and cell therapy in bold biotech push.
NLS Pharmaceutics AG (NASDAQ: NLSP) shares dropped over 15% to close at $1.05 after key merger developments.
NLS Pharmaceutics AG, NLSP
The drop followed confirmation that Nasdaq approved the upcoming merger between NLS, NLS Israel, and Kadimastem Ltd. All critical conditions for the merger were completed or waived, setting the final closing for October 30, 2025.
Trading in Kadimastem shares on the Tel Aviv Stock Exchange will pause until delisting on October 31. NLS will undergo a significant structural shift as part of this merger. The resulting company, NewCelX Ltd., will begin trading on Nasdaq under ticker symbol “NCEL” starting October 31.
Kadimastem Delisting and Share Exchange to Reshape Market Presence
Kadimastem Ltd. (TASE: KDST) is preparing to conclude its trading presence on the TASE following the merger. This transition includes a temporary suspension of trading activity, scheduled to take effect before final delisting on October 31. The restructuring marks Kadimastem’s complete market shift from TASE to Nasdaq.
The share exchange ratio has been finalized at 7.06 NLS shares for each Kadimastem share before the reverse split. After implementing a 1-for-10 reverse split, the final ratio adjusts to 0.706 NLS shares per Kadimastem share. The updated ratio reflects consolidation for listing alignment under Nasdaq regulations.
Kadimastem shareholders will receive their NewCelX shares into their brokerage accounts by November 3 or shortly after. The new shares will become tradeable on November 4. This schedule provides a seamless transition for existing Kadimastem holders to the new Nasdaq-listed entity.
NLS Rebranding as NewCelX Ltd. Targets Expanded Biotech Footprint
NLS Pharmaceutics is transitioning into NewCelX Ltd., with a fresh focus on combined expertise and broader market exposure. The new entity will continue developing treatments for central nervous system and neurodegenerative disorders. It brings together Swiss and Israeli innovation in a unified, publicly listed structure.
NewCelX plans to capitalize on Kadimastem’s advanced cell therapy pipeline and NLS’s neuropharma portfolio. Together, they aim to expand clinical-stage development in high-need disease areas. The combined company aims to enhance long-term growth through integrated research and development, as well as broader investor access.
NLS’s current shareholders will hold equity in NewCelX, aligning future gains with the new corporate roadmap. The rebranding follows strategic moves to consolidate biotech assets under a unified Nasdaq platform. Both companies emphasize the merger’s role in creating stronger therapeutic value globally.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
